# Management and Outcomes of Patients at a Specialty Clinic for Clostridioides difficile Infection

**Authors:** Aaron Hunt, Larry H Danziger, Stuart Johnson, Andrew M Skinner

PMC · DOI: 10.1093/ofid/ofae153 · Open Forum Infectious Diseases · 2024-03-15

## TL;DR

A specialty clinic for Clostridioides difficile infection improved patient outcomes by managing treatment and reducing recurrence rates.

## Contribution

The study demonstrates the effectiveness of a dedicated CDI clinic in managing infections and reducing recurrence.

## Key findings

- Nearly half of patients referred to the CDI clinic did not require further treatment.
- The 60-day CDI recurrence rate was 16.9%.
- Specialized CDI management may improve clinical outcomes.

## Abstract

Vancomycin and fidaxomicin taper regimens were the most common treatment strategies employed but nearly half of patients (40/83) referred to our Clostridioides difficile infection (CDI) clinic did not require further treatment. The overall 60-day CDI recurrence rate was 16.9% (11/65). CDI management at a dedicated clinic may improve clinical outcomes.

## Linked entities

- **Chemicals:** Vancomycin (PubChem CID 14969), fidaxomicin (PubChem CID 10034073)
- **Diseases:** CDI (MONDO:0015790)

## Full-text entities

- **Diseases:** CDI (MESH:D003015)
- **Chemicals:** fidaxomicin (MESH:D000077732), Vancomycin (MESH:D014640)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11045021/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC11045021/full.md

## References

14 references — full list in the complete paper: https://tomesphere.com/paper/PMC11045021/full.md

---
Source: https://tomesphere.com/paper/PMC11045021